



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/413185/2010

European Medicines Agency decision

P/115/2010

of 7 July 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312) (EMA-000716-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/115/2010

of 7 July 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312) (EMA-000716-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Novartis Europharm Limited on 10 September 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 May 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312), film-coated tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312), film-coated tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312), film-coated tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, United Kingdom.

Done at London, 7 July 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/269322/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000716-PIP01-09

Scope of the application

Active substance(s):

Trifluoromethyl-benzyloxyimino-ethyl-carboxylic acid derivative (BAF312)

Condition(s):

Multiple sclerosis

Pharmaceutical form(s):

Film-coated tablets

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted for agreement to the European Medicines Agency on 10 September 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 October 2009.

Supplementary information was provided by the applicant on 25 February 2010.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation ,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member(s) agree(s) with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 21 May 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed Paediatric Investigation Plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Condition(s)

Multiple sclerosis

2. Waiver

2.1. Condition

Multiple sclerosis

The waiver applies to:

- All subsets of the paediatric population from birth to less than 10 years of age
- for film-coated tablets, oral use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Multiple sclerosis

3.1.1. Indication targeted by the PIP

Treatment of children/adolescent patients (10 – 18 year old) with relapsing forms of multiple sclerosis.

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age.

3.1.3. Pharmaceutical form(s)

Film-coated tablets

3.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	1. Pre- and postnatal 13-week oral gavage study in rats.
Clinical	1	2. Open-label, randomised, multicentre, multiple dose, active controlled, parallel-group efficacy and safety study of BAF312 in children from 10 to less than 18 years of age with multiple sclerosis with relapsing remitting course.

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues and efficacy in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2021
Deferral for one or more studies contained in the paediatric investigation plan:	Yes